Oral α4β7 Integrin Antagonists for Effective IBD Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a lack of effective orally bioavailable integrin inhibitors for the treatment of various human diseases, including inflammatory bowel disease, ileoanal anastomosis, eosinophilic esophagitis, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, chronic bronchitis, chronic sinusitis, asthma, graft versus host disease, chronic inflammatory diseases of the lung, HIV, and hematological tumor.

Innovation Solution

Development of compounds that antagonize the α4β7 integrin for use in treating these conditions, including specific chemical structures and pharmaceutical formulations for oral administration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If monoclonal antibodies are used to inhibit α4β7 integrin, then therapeutic benefits are achieved for inflammatory bowel disease, but the treatment requires injectable administration and cannot be taken orally

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidroute of administration

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent changes the chemical structure parameters from large protein-based monoclonal antibodies to smaller small-molecule compounds with specific chemical formulas (Formula I and Formula II). This structural parameter change enables oral bioavailability while maintaining integrin binding capability, resolving the contradiction between therapeutic efficacy and ease of administration.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces the biological mechanism of monoclonal antibodies with a chemical mechanism using small-molecule compounds that bind to α4β7 integrin. This substitution allows the drug to be absorbed through the gastrointestinal tract via oral administration, eliminating the need for injection while preserving the therapeutic effect of integrin inhibition.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Ease of operation

If integrin inhibitors are developed for oral administration, then ease of operation is improved, but there is a lack of effective orally bioavailable compounds with proven therapeutic efficacy

Engineering Contradiction:

Improveroute of administrationVSAvoidtherapeutic efficacy

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent optimizes molecular weight, lipophilicity, and chemical structure parameters of the compounds in Formula I and Formula II to achieve both oral bioavailability and high affinity binding to α4β7 integrin. This dual optimization of physical-chemical parameters resolves the contradiction between ease of administration and therapeutic efficacy.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentEP3773573B1Antagonists of human integrin (alpha4)(BETA7)

Publication Date: 2026.03.18 MORPHIC THERAPEUTIC INC

AI summary

Disclosed are small molecule antagonists of α4β7 integrin, and methods of using them to treat a number of specific diseases or conditions.